Madrigal Pharmaceuticals (MDGL) Interest Coverage Ratio (2016 - 2026)
Madrigal Pharmaceuticals (MDGL) reported Interest Coverage Ratio of 11.89 for Q1 2026, up 50.58% year-over-year from 7.89 in Q1 2025, and down 65.46% quarter-over-quarter from 7.18 in Q4 2025.
Madrigal Pharmaceuticals (MDGL) Interest Coverage Ratio (2016 - 2026) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has 6 years of Interest Coverage Ratio data on file, last reported at 11.89 in Q1 2026.
- Interest Coverage Ratio for Q1 2026 came in at 11.89, up 50.58% year-over-year; the trailing twelve-month figure through Mar 2026 was 11.69 (up 61.14% YoY), and the FY2025 annual result was 13.45, up 60.36% from the prior year.
- Interest Coverage Ratio slipped to 11.89 in Q1 2026 per MDGL's latest filing, from 7.18 in the prior quarter.
- Over five years, Interest Coverage Ratio peaked at 7.18 in Q4 2025 and troughed at 90.09 in Q2 2022.
- A 5-year average of 32.69 and a median of 29.65 in 2023 frame the typical range for Interest Coverage Ratio.
- The sharpest annual moves came in 2024 and 2025: Interest Coverage Ratio sank 49.19% in 2024, then jumped 67.47% in 2025.
- A 5-year view of Interest Coverage Ratio shows it stood at 50.71 in 2022, then surged by 41.81% to 29.51 in 2023, then surged by 35.11% to 19.15 in 2024, then surged by 62.48% to 7.18 in 2025, then slumped by 65.46% to 11.89 in 2026.
- Business Quant data shows MDGL's Interest Coverage Ratio at 11.89 in Q1 2026, 7.18 in Q4 2025, and 15.3 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3.58 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 11.50 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -258.33 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 547.67 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 11.79 |
| 10 | Madrigal Pharmaceuticals | 14.67 Bn | 14.44 Bn | - | -11.89 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -11.89 |
| Dec 31, 2025 | -7.18 |
| Sep 30, 2025 | -15.30 |
| Jun 30, 2025 | -14.46 |
| Mar 31, 2025 | -24.06 |
| Dec 31, 2024 | -19.15 |
| Sep 30, 2024 | -31.61 |
| Jun 30, 2024 | -44.46 |
| Mar 31, 2024 | -39.61 |
| Dec 31, 2023 | -29.51 |
| Sep 30, 2023 | -28.12 |
| Jun 30, 2023 | -29.80 |
| Mar 31, 2023 | -33.53 |
| Dec 31, 2022 | -50.71 |
| Sep 30, 2022 | -53.54 |
| Jun 30, 2022 | -90.09 |
| Dec 31, 2016 | -596.54 |
| Sep 30, 2016 | 1,083.92 |
| Jun 30, 2016 | -11.09 |
| Mar 31, 2016 | -0.76 |